Citigroup’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.49M | Buy |
66,603
+41,516
| +165% | +$1.54M | ﹤0.01% | 2769 |
|
|
2026
Q1 | $911K | Buy |
25,087
+8,750
| +54% | +$391K | ﹤0.01% | 3171 |
|
|
2025
Q4 | $760K | Sell |
16,337
-4,459
| -21% | -$199K | ﹤0.01% | 3312 |
|
|
2025
Q3 | $866K | Sell |
20,796
-35,983
| -63% | -$1.15M | ﹤0.01% | 3249 |
|
|
2025
Q2 | $1.63M | Sell |
56,779
-93,271
| -62% | -$2.88M | ﹤0.01% | 2818 |
|
|
2025
Q1 | $5.03M | Buy |
150,050
+29,291
| +24% | +$1.09M | ﹤0.01% | 1891 |
|
|
2024
Q4 | $6.17M | Buy |
120,759
+55,934
| +86% | +$3.13M | ﹤0.01% | 1755 |
|
|
2024
Q3 | $3.31M | Buy |
64,825
+33,755
| +109% | +$1.74M | ﹤0.01% | 2206 |
|
|
2024
Q2 | $1.39M | Sell |
31,070
-216,980
| -87% | -$10M | ﹤0.01% | 2645 |
|
|
2024
Q1 | $11.6M | Buy |
248,050
+145,739
| +142% | +$5.7M | 0.01% | 1165 |
|
|
2023
Q4 | $3.64M | Buy |
102,311
+18,539
| +22% | +$569K | ﹤0.01% | 1805 |
|
|
2023
Q3 | $2.49M | Buy |
83,772
+28,388
| +51% | +$585K | ﹤0.01% | 1845 |
|
|
2023
Q2 | $998K | Sell |
55,384
-48,433
| -47% | -$966K | ﹤0.01% | 2843 |
|
|
2023
Q1 | $1.67M | Buy |
103,817
+54,946
| +112% | +$1.02M | ﹤0.01% | 2144 |
|
|
2022
Q4 | $894K | Sell |
48,871
-21,615
| -31% | -$381K | ﹤0.01% | 2704 |
|
|
2022
Q3 | $1.38M | Buy |
70,486
+20,506
| +41% | +$418K | ﹤0.01% | 2455 |
|
|
2022
Q2 | $932K | Buy |
49,980
+34,510
| +223% | +$689K | ﹤0.01% | 2720 |
|
|
2022
Q1 | $340K | Sell |
15,470
-36,753
| -70% | -$744K | ﹤0.01% | 3759 |
|
|
2021
Q4 | $1.48M | Buy |
52,223
+28,460
| +120% | +$702K | ﹤0.01% | 2874 |
|
|
2021
Q3 | $500K | Buy |
23,763
+19,122
| +412% | +$400K | ﹤0.01% | 3611 |
|
|
2021
Q2 | $87K | Buy |
4,641
+1,835
| +65% | +$32.2K | ﹤0.01% | 4568 |
|
|
2021
Q1 | $43K | Sell |
2,806
-7,455
| -73% | -$116K | ﹤0.01% | 4778 |
|
|
2020
Q4 | $145K | Buy |
10,261
+5,254
| +105% | +$73.2K | ﹤0.01% | 5237 |
|
|
2020
Q3 | $78K | Sell |
5,007
-1,563
| -24% | -$23.9K | ﹤0.01% | 5284 |
|
|
2020
Q2 | $115K | Buy |
6,570
+3,353
| +104% | +$57.2K | ﹤0.01% | 5462 |
|
|
2020
Q1 | $47K | Buy |
3,217
+966
| +43% | +$19.8K | ﹤0.01% | 6016 |
|
|
2019
Q4 | $56K | Buy |
2,251
+1,067
| +90% | +$20.3K | ﹤0.01% | 6212 |
|
|
2019
Q3 | $18K | Sell |
1,184
-2,459
| -67% | -$47.8K | ﹤0.01% | 6792 |
|
|
2019
Q2 | $92K | Buy |
3,643
+933
| +34% | +$23.1K | ﹤0.01% | 5949 |
|
|
2019
Q1 | $61K | Buy |
2,710
+1,209
| +81% | +$29.7K | ﹤0.01% | 6169 |
|
|
2018
Q4 | $45K | Sell |
1,501
-445
| -23% | -$12.5K | ﹤0.01% | 6314 |
|
|
2018
Q3 | $56K | Buy |
+1,946
| New | +$57.8K | ﹤0.01% | 6424 |
|
Other funds holding CRNX
FCM
DCM
JT
Citigroup's CRNX Position: Q2 2026 in Review
Citigroup increased its Crinetics Pharmaceuticals (CRNX) stake by 165% in Q2 2026, buying an estimated $1.54M and bringing the position to 66,603 shares worth $2.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2769.
Citigroup first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $11.6M in Q1 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Citigroup held 66,603 shares of Crinetics Pharmaceuticals worth $2.49M as of Q2 2026.
- Citigroup bought 41,516 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.54M.
- Crinetics Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2769 holding.
- Citigroup first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Citigroup's Crinetics Pharmaceuticals position peaked at $11.6M in Q1 2024.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.